News

In the trial, all healthy volunteers completed the treatment phase and results are scheduled to be released during the first quarter of 2015. The company is developing BL-8040

Asserting that harmonisation would be the only way for market access to make a step improvement, Bergströmexplained that it was in everyone’s interests, not just those of pharmaceutical

While the data from this study showed KB001-A was generally safe and well-tolerated, the primary endpoint of increased time to need for antibiotics for worsening respiratory tract signs

The study is based on the same science that has shown tremendous progress in the treatment of Knee Osteoarthritis (KOA). Both arthroscopy and the use of magnetic resonance

The FDA orphan drug designation coincides with the positive opinion of the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) regarding NiCord as a treatment for

The study is expected to commence during the first quarter of 2015. CM-24 is directed against CEACAM1, a novel immune checkpoint protein that is expressed on activated effector

Kite previously announced in March 2014 that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for KTE-C19 for the treatment of DLBCL. Further, Kite has

TRV130 is being developed as a first-line intravenous treatment for patients experiencing moderate-to-severe acute pain. The multicenter, randomized, double-blind, placebo- and active-controlled clinical trial is designed to evaluate

As part of the deal, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth about